BCVS Scientific Sessions 2018
In-Person Event
Jul 30 - Aug 02, 2018
San Antonio, Texas, USA
OVERVIEW
14th Annual Basic Cardiovascular Sciences (BCVS) Scientific Session is organized by American Heart Association (AHA) and will be held during Jul 30 - Aug 02, 2018 at Grand Hyatt San Antonio, San Antonio, Texas, United States of America.
The target audience for this medical event is Basic cardiovascular scientists, Molecular/cellular biologists, Physiologists, Translational investigators, Clinical trialists, Practicing cardiologists, Cardiovascular nurses, and pharmacists.
This scientific session has become the premier conference for molecular cardiovascular biology and disease. this conference attracts leading researchers in fields such as microRNAs, cardiac gene, and cell therapy, cardiac development and most recently tissue engineering and iPS cells.
The planned agenda includes 15 fast-paced sessions during 3½ days, set in a forum that promotes the relaxed exchange and discussion of cutting-edge research in molecular and translational cardiovascular biology and disease. The program includes a diversity of speakers representing the best cardiovascular scientists from around the world.
Conference Objectives :
At the conclusion of the conference, participants will be able to:
• Discuss advances in the underlying mechanisms that contribute to pathological cardiac remodeling and development of targeted therapeutic strategies to improve outcomes for patients with CVD.
• Evaluate the most recent evidence on the pathophysiological mechanisms underlying myocardial perfusion injury, supporting the use of cardioprotective strategies, including advances in oxidative stress-activated mechanisms in CVD pathophysiology.
• Discuss recent advances in understanding the complex interplay between signal transduction cascades in modulating apoptotic and functional pathways (mitochondrial, ion channels, metabolism) to identify novel drug targets and preserve functional cardiac myocytes.
• Describe current research exploring the integrated role of novel "omics" technologies and "big data" analytics that may allow for precision medicine and may improve patient outcomes by examining more holistically the pathophysiological mechanisms underlying cardiovascular function.
• Discuss the importance of state-of-the-art clinically relevant reprogrammed human cellular and large animal model systems, including the challenges to bridge the gap between basic science and clinical application of these modalities for improving translational research and outcomes in patients with CVD.
• Discuss challenges and issues arising regarding the pursuit of cardiovascular research, including future research directions, issues of responsibility in research and the move towards translation into clinical practice.
• Describe recent and emerging advances into the genetic and molecular mechanisms driving cardiomyopathy and heart failure that are guiding the development of interventions such as targeted gene therapy and regenerative stem cell therapy.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Basic cardiovascular scientists, Molecular/cellular biologists, Physiologists, Translational investigators, Clinical trialists, Practicing cardiologists, Cardiovascular nurses, and pharmacists.
This scientific session has become the premier conference for molecular cardiovascular biology and disease. this conference attracts leading researchers in fields such as microRNAs, cardiac gene, and cell therapy, cardiac development and most recently tissue engineering and iPS cells.
The planned agenda includes 15 fast-paced sessions during 3½ days, set in a forum that promotes the relaxed exchange and discussion of cutting-edge research in molecular and translational cardiovascular biology and disease. The program includes a diversity of speakers representing the best cardiovascular scientists from around the world.
Conference Objectives :
At the conclusion of the conference, participants will be able to:
• Discuss advances in the underlying mechanisms that contribute to pathological cardiac remodeling and development of targeted therapeutic strategies to improve outcomes for patients with CVD.
• Evaluate the most recent evidence on the pathophysiological mechanisms underlying myocardial perfusion injury, supporting the use of cardioprotective strategies, including advances in oxidative stress-activated mechanisms in CVD pathophysiology.
• Discuss recent advances in understanding the complex interplay between signal transduction cascades in modulating apoptotic and functional pathways (mitochondrial, ion channels, metabolism) to identify novel drug targets and preserve functional cardiac myocytes.
• Describe current research exploring the integrated role of novel "omics" technologies and "big data" analytics that may allow for precision medicine and may improve patient outcomes by examining more holistically the pathophysiological mechanisms underlying cardiovascular function.
• Discuss the importance of state-of-the-art clinically relevant reprogrammed human cellular and large animal model systems, including the challenges to bridge the gap between basic science and clinical application of these modalities for improving translational research and outcomes in patients with CVD.
• Discuss challenges and issues arising regarding the pursuit of cardiovascular research, including future research directions, issues of responsibility in research and the move towards translation into clinical practice.
• Describe recent and emerging advances into the genetic and molecular mechanisms driving cardiomyopathy and heart failure that are guiding the development of interventions such as targeted gene therapy and regenerative stem cell therapy.
Additional details will be posted as soon as they are available.
KEY DATES
30 Jul, 2018
Event Start Date
02 Aug, 2018
Event End Date
SPECIALITIES
CardiologySUGGESTED HOTELS
CONFERENCE VENUE
Grand Hyatt San AntonioRELATED CONFERENCES & LIVE WEBINARS
Quick Links